Natera Inc (NTRA)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$403.95+0.64%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Natera Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	749.53M
EPS	—	-0.105
FY 2026 · Annual
Revenue	$2.85B–$2.91B	2.91B
EPS	—	-1.454
Gross margin	64%–66%	—
R&D	$800M–$900M	—
FY 2027 · Annual
Revenue	—	3.52B
EPS	—	-0.342

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross margin improves to 64%-66% in 2026	Its gross margin is improving, guided at 64%-66%.	Intact	Gross margin falls below 62% in FY26	Gross margin: 64.46% FY2026-Q2; GAAP. Published target: 64%-66%. Target period is not explicitly aligned with this observation. Source published Aug 7, 202664.45553 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Gross margin was 64.7% in 2026-Q1 and 64.5% in 2026-Q2, consistent with guidance of 64% to 66%. Non-GAAP gross margin improved sequentially by 0.5% in 2026-Q2. The trajectory shows stable margin performance aligned with management's stated target. Delivery assessment Oct 24, 2026
Legal wins and regulatory approvals sustain market position	The company won a key legal case and gained regulatory approval in Japan, expanding its market.	Intact	Loss of key legal cases or regulatory approvals	Qualitative: Japan approval secured Japan approval and regulatory wins reported in September 2026; no adverse legal events detected. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
R&D costs maintained between $750 million and $850 million in 2026	A supporting condition in Natera Inc's published investment case. The stated target is $750M-$850M.	Intact	R&D costs exceed $850 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. R&D expenses were $210.7 million in 2026-Q1 and $228.1 million in 2026-Q2, consistent with guidance of $800 million to $900 million for the full year. The trajectory shows management maintaining R&D spending within the guided range. Delivery assessment Oct 24, 2026
Annual revenue reaches about $2.78 billion in 2026	Natera is growing revenue fast, with guidance raised to about $2.78 billion in 2026.	Intact	Annual revenue falls below $2.74 billion in FY26	Revenue: $752.75M FY2026-Q2; GAAP. Published target: ~$2.78B. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026752,750,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5e3d334e-25ac-43bf-b5e3-b9c383ad2ff0. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $696.6 million in 2026-Q1 to $752.8 million in 2026-Q2 (+8.1%). Management raised 2026 annual revenue guidance midpoint by $100 million from $2.78 billion to $2.88 billion. The trajectory is delivering with consistent revenue growth and upward guidance revisions. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.34

$-0.30 → $-0.34 · observed estimates

FY2027 revenue$3.52B

$3.33B → $3.52B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.30	$3,328,214,759	12 / 15
2026-07-25	$-0.20	$3,328,189,090	14 / 21
2026-07-26	$-0.30	$3,328,214,778	12 / 15
2026-07-27	$-0.30	$3,328,214,778	12 / 15
2026-07-28	$-0.20	$3,328,189,090	14 / 21
2026-07-29	$-0.20	$3,328,189,090	14 / 21
2026-07-30	$-0.30	$3,328,214,778	12 / 15
2026-07-31	$-0.30	$3,328,214,778	12 / 15
2026-08-01	$-0.30	$3,328,214,778	12 / 15
2026-08-02	$-0.20	$3,328,246,230	14 / 21
2026-08-03	$-0.30	$3,328,214,778	12 / 15
2026-08-04	$-0.30	$3,328,214,778	12 / 15
2026-08-05	$-0.20	$3,328,246,230	14 / 21
2026-08-06	$-0.30	$3,328,214,778	12 / 15
2026-08-07	$-0.30	$3,328,214,778	12 / 15
2026-08-08	$-0.35	$3,382,090,200	11 / 21
2026-08-09	$-0.35	$3,382,090,200	11 / 21
2026-08-10	$-0.30	$3,328,214,778	12 / 15
2026-08-12	$-0.30	$3,328,214,778	12 / 15
2026-08-13	$-0.30	$3,328,214,778	12 / 15
2026-08-14	$-0.30	$3,328,214,778	12 / 15
2026-08-15	$-0.30	$3,328,214,778	12 / 15
2026-08-16	$-0.30	$3,328,214,778	12 / 15
2026-08-17	$-0.30	$3,328,214,778	12 / 15
2026-08-18	$-0.30	$3,328,214,778	12 / 15
2026-08-19	$-0.30	$3,328,214,778	12 / 15
2026-08-20	$-0.16	$3,478,634,877	12 / 15
2026-08-21	$-0.16	$3,478,634,877	12 / 15
2026-08-22	$-0.16	$3,478,634,877	12 / 15
2026-08-23	$-0.16	$3,478,634,877	12 / 15
2026-08-24	$-0.16	$3,478,634,877	12 / 15
2026-08-25	$-0.16	$3,478,634,877	12 / 15
2026-08-26	$-0.16	$3,478,634,877	12 / 15
2026-08-27	$-0.16	$3,478,634,877	12 / 15
2026-08-28	$-0.16	$3,478,634,877	12 / 15
2026-08-29	$-0.16	$3,478,634,877	12 / 15
2026-08-30	$-0.16	$3,478,634,877	12 / 15
2026-08-31	$-0.16	$3,478,634,877	12 / 15
2026-09-01	$-0.16	$3,478,634,877	12 / 15
2026-09-02	$-0.16	$3,478,634,877	12 / 15
2026-09-03	$-0.16	$3,478,634,877	12 / 15
2026-09-04	$-0.16	$3,478,634,877	12 / 15
2026-09-05	$-0.16	$3,478,634,877	12 / 15
2026-09-06	$-0.16	$3,478,634,877	12 / 15
2026-09-07	$-0.16	$3,478,634,877	12 / 15
2026-09-08	$-0.16	$3,478,634,877	12 / 15
2026-09-09	$-0.16	$3,478,634,877	12 / 15
2026-09-10	$-0.13	$3,488,444,137	13 / 16
2026-09-11	$-0.13	$3,488,444,137	13 / 16
2026-09-12	$-0.13	$3,488,444,137	13 / 17
2026-09-13	$-0.13	$3,488,444,137	13 / 17
2026-09-14	$-0.13	$3,488,444,137	13 / 17
2026-09-15	$-0.13	$3,488,444,137	13 / 17
2026-09-16	$-0.13	$3,488,444,137	13 / 17
2026-09-17	$-0.13	$3,488,444,137	13 / 17
2026-09-18	$-0.13	$3,488,444,137	13 / 17
2026-09-19	$-0.13	$3,488,444,137	13 / 17
2026-09-20	$-0.13	$3,488,444,137	13 / 17
2026-09-21	$-0.13	$3,488,444,137	13 / 17
2026-09-22	$-0.14	$3,488,444,137	13 / 17
2026-09-23	$-0.14	$3,488,444,137	13 / 17
2026-09-24	$-0.14	$3,488,441,467	13 / 17
2026-09-25	$-0.14	$3,488,441,467	13 / 17
2026-09-26	$-0.14	$3,488,441,467	13 / 17
2026-09-27	$-0.14	$3,488,441,467	13 / 17
2026-09-28	$-0.14	$3,488,441,467	13 / 17
2026-09-29	$-0.14	$3,488,441,467	13 / 17
2026-09-30	$-0.14	$3,501,547,897	13 / 17
2026-10-01	$-0.14	$3,501,547,897	13 / 16
2026-10-02	$-0.17	$3,506,752,443	13 / 16
2026-10-03	$-0.17	$3,506,752,443	12 / 16
2026-10-04	$-0.17	$3,506,752,443	13 / 16
2026-10-05	$-0.17	$3,506,752,443	13 / 16
2026-10-06	$-0.17	$3,508,070,625	13 / 16
2026-10-07	$-0.19	$3,508,070,625	13 / 16
2026-10-08	$-0.21	$3,508,852,884	13 / 16
2026-10-09	$-0.21	$3,508,852,884	13 / 16
2026-10-10	$-0.21	$3,508,852,884	13 / 16
2026-10-11	$-0.21	$3,508,852,884	13 / 16
2026-10-12	$-0.21	$3,508,852,884	13 / 16
2026-10-13	$-0.25	$3,513,512,972	13 / 16
2026-10-14	$-0.27	$3,514,913,777	12 / 16
2026-10-15	$-0.28	$3,514,912,902	12 / 16
2026-10-16	$-0.28	$3,514,912,902	12 / 16
2026-10-17	$-0.28	$3,514,912,902	12 / 16
2026-10-18	$-0.28	$3,514,912,902	12 / 16
2026-10-19	$-0.28	$3,514,912,902	12 / 16
2026-10-20	$-0.33	$3,514,910,702	12 / 16
2026-10-21	$-0.33	$3,514,894,720	12 / 16
2026-10-22	$-0.33	$3,514,894,720	12 / 16
2026-10-23	$-0.35	$3,516,246,077	12 / 16
2026-10-24	$-0.34	$3,515,234,892	12 / 16

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	17	2
2026-06-01	19	3
2026-07-01	19	3
2026-08-01	19	3
2026-09-01	21	3
2026-10-01	22	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 22 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades8 maintains

Recent actions · Sep 25–Oct 24 · 8 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Roth CapitalOct 22

$475.00New observation · no comparable prior

Canaccord GenuityOct 19 · prior Aug 7

$375.00 → $500.00+33.3%

Morgan StanleyOct 12 · prior Aug 10

$355.00 → $435.00+22.5%

BarclaysOct 7 · prior Aug 7

$340.00 → $475.00+39.7%

GuggenheimOct 1 · prior Aug 12

$360.00 → $475.00+31.9%

RBC CapitalSep 25 · prior Aug 7

$350.00 → $460.00+31.4%

$0$275.00$550.00

5 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross margin improves to 64%-66% in 2026Gross margin: 64.46%
R&D costs maintained between $750 million and $850 million in 2026Direct metric needs a verified mapping
Annual revenue reaches about $2.78 billion in 2026Revenue: $752.75M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-28.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Natera Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented, loss-making business, not yet a proven profitable compounder. The long-term thesis is on watch: revenue progress is encouraging, but recent performance has lagged its industry cohort and the latest quarter was missed.

What's priced into Natera Inc

The valuation is described as justified, with a modest premium versus peers and low confidence in the valuation model. The evidence points to some expectations for future opportunity, but does not show a large expectations gap; no fragility signals have fired.

What the fundamentals likely do

Near term, revenue has grown and management raised its annual revenue guidance midpoint, while gross margin stayed within its stated range. R&D spending is within guidance, but margins and costs remain mixed, and erratic earnings surprises make execution worth watching.

What Natera Inc hinges on

The thesis depends on revenue growth continuing while gross margins remain stable and R&D costs stay within guidance. A guidance cut or weaker jobs data would add risk; continued strong results and higher guidance from sector bellwethers could support the sector backdrop.